Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Construction and development specialist Seddon has completed enabling work to support the installation of UK-first Siemens Healthineers cancer imaging technology at a site on the Wirral.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with treatment-resistant depression. Researchers tracked changes in a critical brain receptor ...

Noozhawk republishes news articles from KFF Health News on national and state health-related issues that affect Santa Barbara County readers.  Samantha ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

RadNet's management reported record Q4 2025 revenue, while underlying organic growth of the base imaging business is still healthy. See why RDNT stock is a strong buy.

The Life Vincent Pallotti Hospital in Cape Town has recently improved its cancer diagnostics by installing a digital PET-CT (positron emission tomography-computed tomography) scanner. This scanner, a ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...